MX380968B - Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. - Google Patents
Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.Info
- Publication number
- MX380968B MX380968B MX2016008108A MX2016008108A MX380968B MX 380968 B MX380968 B MX 380968B MX 2016008108 A MX2016008108 A MX 2016008108A MX 2016008108 A MX2016008108 A MX 2016008108A MX 380968 B MX380968 B MX 380968B
- Authority
- MX
- Mexico
- Prior art keywords
- angiotensin
- mcg
- dose
- equivalent
- treatment
- Prior art date
Links
- 102000005862 Angiotensin II Human genes 0.000 title abstract 2
- 101800000733 Angiotensin-2 Proteins 0.000 title abstract 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title abstract 2
- 229950006323 angiotensin ii Drugs 0.000 title abstract 2
- 208000001953 Hypotension Diseases 0.000 title 1
- 230000036543 hypotension Effects 0.000 title 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 3
- 229960002748 norepinephrine Drugs 0.000 abstract 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 3
- 150000003943 catecholamines Chemical class 0.000 abstract 2
- 230000004872 arterial blood pressure Effects 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917576P | 2013-12-18 | 2013-12-18 | |
| US201461955706P | 2014-03-19 | 2014-03-19 | |
| PCT/US2014/071186 WO2015095535A1 (en) | 2013-12-18 | 2014-12-18 | Angiotensin ii alone or in combination for the treatment of hypotension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016008108A MX2016008108A (es) | 2017-03-09 |
| MX380968B true MX380968B (es) | 2025-03-12 |
Family
ID=53367119
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008108A MX380968B (es) | 2013-12-18 | 2014-12-18 | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. |
| MX2020011190A MX2020011190A (es) | 2013-12-18 | 2016-06-17 | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011190A MX2020011190A (es) | 2013-12-18 | 2016-06-17 | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US9220745B2 (OSRAM) |
| EP (2) | EP3607962B1 (OSRAM) |
| JP (4) | JP6824739B2 (OSRAM) |
| KR (4) | KR102399383B1 (OSRAM) |
| CN (4) | CN111920939A (OSRAM) |
| AU (3) | AU2014364528C1 (OSRAM) |
| BR (1) | BR112016013961A2 (OSRAM) |
| CA (1) | CA2933601A1 (OSRAM) |
| CY (1) | CY1122604T1 (OSRAM) |
| DK (2) | DK2986308T3 (OSRAM) |
| EA (1) | EA037823B1 (OSRAM) |
| ES (1) | ES2771749T3 (OSRAM) |
| FI (1) | FI3607962T3 (OSRAM) |
| HR (1) | HRP20200009T1 (OSRAM) |
| HU (1) | HUE047062T2 (OSRAM) |
| IL (1) | IL246162B (OSRAM) |
| LT (1) | LT2986308T (OSRAM) |
| MX (2) | MX380968B (OSRAM) |
| NZ (1) | NZ721089A (OSRAM) |
| PL (1) | PL2986308T3 (OSRAM) |
| PT (2) | PT2986308T (OSRAM) |
| RS (1) | RS59804B1 (OSRAM) |
| SI (1) | SI2986308T1 (OSRAM) |
| SM (1) | SMT202000018T1 (OSRAM) |
| WO (1) | WO2015095535A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| EA037823B1 (ru) | 2013-12-18 | 2021-05-25 | Дзе Джордж Вашингтон Юниверсити, Э Конгрешионэл Чартеред Нон-Фор-Профит Корпорейшн | Способ лечения субъекта, испытывающего интенсивный шок и получающего лечение катехоламином или вазопрессином |
| TWI754225B (zh) * | 2014-07-08 | 2022-02-01 | 美商拉荷亞製藥公司 | 治療低血壓之方法 |
| US9919022B2 (en) | 2015-03-20 | 2018-03-20 | Arthur J. ATKINSON, JR. | Use of angiotensin II (AII) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
| TW201735913A (zh) * | 2016-01-07 | 2017-10-16 | 拉荷亞製藥公司 | 投與血管加壓劑之方法 |
| US10406201B2 (en) * | 2016-01-07 | 2019-09-10 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| WO2018191678A1 (en) * | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| TW201927331A (zh) * | 2017-12-15 | 2019-07-16 | 美商拉荷亞製藥公司 | 血管收縮素組合物及與其相關之方法 |
| WO2023244552A1 (en) * | 2022-06-15 | 2023-12-21 | Virginia Commonwealth University | Methods for fluid resuscitation of an organ donor |
| JP2025538841A (ja) * | 2022-12-12 | 2025-11-28 | プロレタリアート セラピューティクス， インコーポレイテッド | 心損傷を処置する方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU181008B (en) | 1980-01-18 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position |
| US5216025A (en) | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| EP1401864A1 (en) | 2001-06-04 | 2004-03-31 | Human Genome Sciences | Methods and compositions for modulating ace-2 activity |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| NO20034952D0 (no) | 2003-11-06 | 2003-11-06 | Amersham Health As | Farmasöytiske forbindelser |
| US7785566B2 (en) | 2003-11-06 | 2010-08-31 | Ge Healthcare, Inc. | Pharmaceutical compounds |
| FR2880807B1 (fr) * | 2005-01-19 | 2007-04-13 | Aguettant Sa Lab | Composition pharmaceutique injectable |
| WO2007040636A1 (en) | 2005-09-29 | 2007-04-12 | Fibrogen, Inc. | Methods for reducing blood pressure |
| US20090304818A1 (en) | 2005-12-30 | 2009-12-10 | May Clive N | Method of treatment |
| WO2007146900A2 (en) | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| WO2008130217A1 (en) * | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| BRPI0719319A2 (pt) | 2006-11-17 | 2014-02-04 | Da Volterra | Liberação colônica usando contas de zn/pectina com um revestimento de eudragit |
| WO2009009907A1 (en) * | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
| EP2161030A1 (en) * | 2008-09-09 | 2010-03-10 | Rijksuniversiteit te Groningen | Oxytocin formulations and uses thereof |
| EP2350649A4 (en) | 2008-11-28 | 2012-11-14 | Abbott Lab | STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME |
| US9572856B2 (en) * | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| FR2959414B1 (fr) * | 2010-04-30 | 2016-01-08 | Luc Quintin | Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire |
| WO2012009545A1 (en) | 2010-07-14 | 2012-01-19 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists |
| JP6522584B2 (ja) | 2013-04-26 | 2019-05-29 | ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ | 腎不全を処置するための組成物及び方法 |
| EA037823B1 (ru) | 2013-12-18 | 2021-05-25 | Дзе Джордж Вашингтон Юниверсити, Э Конгрешионэл Чартеред Нон-Фор-Профит Корпорейшн | Способ лечения субъекта, испытывающего интенсивный шок и получающего лечение катехоламином или вазопрессином |
| US20150286797A1 (en) | 2014-04-02 | 2015-10-08 | David R. Ratto | System and method for administering medication |
| TWI754225B (zh) | 2014-07-08 | 2022-02-01 | 美商拉荷亞製藥公司 | 治療低血壓之方法 |
| TW201735913A (zh) | 2016-01-07 | 2017-10-16 | 拉荷亞製藥公司 | 投與血管加壓劑之方法 |
| US10406201B2 (en) | 2016-01-07 | 2019-09-10 | La Jolla Pharma, Llc | Methods for administering angiotensin II |
| WO2018191678A1 (en) | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| TW201927331A (zh) | 2017-12-15 | 2019-07-16 | 美商拉荷亞製藥公司 | 血管收縮素組合物及與其相關之方法 |
-
2014
- 2014-12-18 EA EA201691258A patent/EA037823B1/ru unknown
- 2014-12-18 BR BR112016013961A patent/BR112016013961A2/pt not_active Application Discontinuation
- 2014-12-18 NZ NZ721089A patent/NZ721089A/en unknown
- 2014-12-18 PT PT148726847T patent/PT2986308T/pt unknown
- 2014-12-18 DK DK14872684.7T patent/DK2986308T3/da active
- 2014-12-18 EP EP19197866.7A patent/EP3607962B1/en active Active
- 2014-12-18 US US14/575,127 patent/US9220745B2/en active Active
- 2014-12-18 CN CN202010824424.5A patent/CN111920939A/zh active Pending
- 2014-12-18 AU AU2014364528A patent/AU2014364528C1/en active Active
- 2014-12-18 RS RS20200021A patent/RS59804B1/sr unknown
- 2014-12-18 KR KR1020167019427A patent/KR102399383B1/ko active Active
- 2014-12-18 DK DK19197866.7T patent/DK3607962T3/da active
- 2014-12-18 WO PCT/US2014/071186 patent/WO2015095535A1/en not_active Ceased
- 2014-12-18 FI FIEP19197866.7T patent/FI3607962T3/fi active
- 2014-12-18 SM SM20200018T patent/SMT202000018T1/it unknown
- 2014-12-18 EP EP14872684.7A patent/EP2986308B1/en active Active
- 2014-12-18 CN CN201480075899.1A patent/CN106061493A/zh active Pending
- 2014-12-18 CA CA2933601A patent/CA2933601A1/en active Pending
- 2014-12-18 PL PL14872684T patent/PL2986308T3/pl unknown
- 2014-12-18 CN CN202411722811.2A patent/CN119700926A/zh active Pending
- 2014-12-18 SI SI201431450T patent/SI2986308T1/sl unknown
- 2014-12-18 ES ES14872684T patent/ES2771749T3/es active Active
- 2014-12-18 KR KR1020227004084A patent/KR20220028125A/ko not_active Ceased
- 2014-12-18 KR KR1020237012136A patent/KR20230051721A/ko not_active Ceased
- 2014-12-18 CN CN202011494632.XA patent/CN112546197A/zh active Pending
- 2014-12-18 PT PT191978667T patent/PT3607962T/pt unknown
- 2014-12-18 HR HRP20200009TT patent/HRP20200009T1/hr unknown
- 2014-12-18 MX MX2016008108A patent/MX380968B/es unknown
- 2014-12-18 LT LTEP14872684.7T patent/LT2986308T/lt unknown
- 2014-12-18 JP JP2016539318A patent/JP6824739B2/ja active Active
- 2014-12-18 KR KR1020247034828A patent/KR20240154702A/ko active Pending
- 2014-12-18 HU HUE14872684A patent/HUE047062T2/hu unknown
-
2015
- 2015-11-13 US US14/941,301 patent/US10028995B2/en active Active
-
2016
- 2016-06-09 IL IL246162A patent/IL246162B/en active IP Right Grant
- 2016-06-17 MX MX2020011190A patent/MX2020011190A/es unknown
-
2018
- 2018-03-01 US US15/909,617 patent/US10493124B2/en active Active
- 2018-09-19 US US16/135,608 patent/US10765722B2/en active Active
-
2019
- 2019-04-12 US US16/382,850 patent/US11096983B2/en active Active
- 2019-08-23 JP JP2019153144A patent/JP7175506B2/ja active Active
-
2020
- 2020-01-13 CY CY20201100026T patent/CY1122604T1/el unknown
- 2020-11-26 AU AU2020277230A patent/AU2020277230A1/en not_active Abandoned
-
2021
- 2021-07-20 US US17/380,311 patent/US11559559B2/en active Active
-
2022
- 2022-07-14 JP JP2022113327A patent/JP2022137224A/ja not_active Withdrawn
-
2023
- 2023-01-23 US US18/157,933 patent/US20230226141A1/en not_active Abandoned
-
2024
- 2024-09-18 AU AU2024219851A patent/AU2024219851A1/en active Pending
-
2025
- 2025-05-09 JP JP2025078759A patent/JP2025114753A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380968B (es) | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| MX2015010190A (es) | Metodos de tratamiento topico para infecciones microbianas. | |
| MX2015014512A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| EA202091446A1 (ru) | Способы лечения хронических воспалительных заболеваний | |
| CO2019009000A2 (es) | Combinaciones farmacéuticas para tratar cáncer | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| MX2016002307A (es) | Tratamiento para el cancer. | |
| MX374354B (es) | Método de curación de heridas. | |
| EA201790220A1 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
| BR112016014099A2 (pt) | método de tratamento de feridas | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
| EA202092463A1 (ru) | Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии | |
| CL2019002239A1 (es) | Métodos de tratamiento de cánceres pediátricos. (divisional solicitud 201802807) | |
| UA106472U (uk) | Засіб для лікування дерматологічних захворювань | |
| UA106471U (uk) | Засіб для лікування дерматологічних захворювань | |
| EA201700347A2 (ru) | Средство для эффективного купирования острого и/или хронического болевого синдрома и способ его применения | |
| MX381307B (es) | Métodos y sistemas para tratar fluidos y dispositivos médicos. |